Cargando…

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction

The effectiveness of phosphodiesterase type 5 inhibitors (PDE5-Is) for erectile dysfunction (ED) varies considerably among trials, but available studies investigating the factors that affect the effectiveness are few and findings are not consistent. A systematic search was performed in PubMed, Cochr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Jin-Qiu, Mao, Chen, Yang, Zu-Yao, Fu, Xiao-Hong, Wong, Samuel Y, Tang, Jin-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736358/
https://www.ncbi.nlm.nih.gov/pubmed/25966626
http://dx.doi.org/10.4103/1008-682X.154304
_version_ 1782413266787500032
author Yuan, Jin-Qiu
Mao, Chen
Yang, Zu-Yao
Fu, Xiao-Hong
Wong, Samuel Y
Tang, Jin-Ling
author_facet Yuan, Jin-Qiu
Mao, Chen
Yang, Zu-Yao
Fu, Xiao-Hong
Wong, Samuel Y
Tang, Jin-Ling
author_sort Yuan, Jin-Qiu
collection PubMed
description The effectiveness of phosphodiesterase type 5 inhibitors (PDE5-Is) for erectile dysfunction (ED) varies considerably among trials, but available studies investigating the factors that affect the effectiveness are few and findings are not consistent. A systematic search was performed in PubMed, Cochrane Library, and EMBASE to identify randomized controlled trials comparing PDE5-Is with placebo for the treatment of ED. The methodological quality of included studies was assessed by the Cochrane Collaboration's tool for assessing risk of bias. The associations between prespecified study-level factors and effectiveness were tested by a random effects meta-regression model. This study included 93 trials with 26 139 patients. When all PDE5-Is were grouped together, Caucasian ethnicity was associated with 15.636% (95% confidence interval [CI]: 0.858% to 32.579%) increase in risk ratio (RR) for Global Assessment Questionnaire question-1 (GAQ-1), and 1.473 (95% CI: 0.406 to 2.338) score increase in mean difference (MD) for posttreatment International Index of Erectile Function-Erectile Function domain score (IIEF-EF), compared to Asian ethnicity. A one-score increase in baseline IIEF-EF was associated with −5.635% (95% CI: −9.120% to −2.017%) reduction in RR for GAQ-1, and −0.229 (95% CI: −0.425 to −0.042) score decrease in MD for posttreatment IIEF-EF. In conclusion, PDE5-Is are more effective in Caucasians than Asians, and in patients with more severe ED.
format Online
Article
Text
id pubmed-4736358
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-47363582016-02-04 A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction Yuan, Jin-Qiu Mao, Chen Yang, Zu-Yao Fu, Xiao-Hong Wong, Samuel Y Tang, Jin-Ling Asian J Androl Original Article The effectiveness of phosphodiesterase type 5 inhibitors (PDE5-Is) for erectile dysfunction (ED) varies considerably among trials, but available studies investigating the factors that affect the effectiveness are few and findings are not consistent. A systematic search was performed in PubMed, Cochrane Library, and EMBASE to identify randomized controlled trials comparing PDE5-Is with placebo for the treatment of ED. The methodological quality of included studies was assessed by the Cochrane Collaboration's tool for assessing risk of bias. The associations between prespecified study-level factors and effectiveness were tested by a random effects meta-regression model. This study included 93 trials with 26 139 patients. When all PDE5-Is were grouped together, Caucasian ethnicity was associated with 15.636% (95% confidence interval [CI]: 0.858% to 32.579%) increase in risk ratio (RR) for Global Assessment Questionnaire question-1 (GAQ-1), and 1.473 (95% CI: 0.406 to 2.338) score increase in mean difference (MD) for posttreatment International Index of Erectile Function-Erectile Function domain score (IIEF-EF), compared to Asian ethnicity. A one-score increase in baseline IIEF-EF was associated with −5.635% (95% CI: −9.120% to −2.017%) reduction in RR for GAQ-1, and −0.229 (95% CI: −0.425 to −0.042) score decrease in MD for posttreatment IIEF-EF. In conclusion, PDE5-Is are more effective in Caucasians than Asians, and in patients with more severe ED. Medknow Publications & Media Pvt Ltd 2016 2015-05-11 /pmc/articles/PMC4736358/ /pubmed/25966626 http://dx.doi.org/10.4103/1008-682X.154304 Text en Copyright: © Asian Journal of Andrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution NonCommercial ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Yuan, Jin-Qiu
Mao, Chen
Yang, Zu-Yao
Fu, Xiao-Hong
Wong, Samuel Y
Tang, Jin-Ling
A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
title A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
title_full A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
title_fullStr A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
title_full_unstemmed A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
title_short A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
title_sort meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736358/
https://www.ncbi.nlm.nih.gov/pubmed/25966626
http://dx.doi.org/10.4103/1008-682X.154304
work_keys_str_mv AT yuanjinqiu ametaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT maochen ametaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT yangzuyao ametaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT fuxiaohong ametaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT wongsamuely ametaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT tangjinling ametaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT yuanjinqiu metaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT maochen metaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT yangzuyao metaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT fuxiaohong metaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT wongsamuely metaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction
AT tangjinling metaregressionevaluatingtheeffectivenessandprognosticfactorsoforalphosphodiesterasetype5inhibitorsforthetreatmentoferectiledysfunction